CYMABAY THERAPEUTICS INC's ticker is CBAY and the CUSIP is 23257D103. A total of 123 filers reported holding CYMABAY THERAPEUTICS INC in Q3 2020. The put-call ratio across all filers is 0.29 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $589,169 | +56.1% | 39,515 | +14.7% | 0.00% | – |
Q2 2023 | $377,392 | +95.2% | 34,465 | +55.5% | 0.00% | – |
Q1 2023 | $193,314 | +7.1% | 22,169 | -23.0% | 0.00% | – |
Q4 2022 | $180,457 | -1.4% | 28,781 | -44.8% | 0.00% | – |
Q3 2022 | $183,000 | -30.2% | 52,185 | -41.2% | 0.00% | – |
Q2 2022 | $262,000 | -13.8% | 88,712 | -9.1% | 0.00% | – |
Q1 2022 | $304,000 | +16.5% | 97,604 | +26.3% | 0.00% | – |
Q4 2021 | $261,000 | -13.9% | 77,267 | -7.0% | 0.00% | – |
Q3 2021 | $303,000 | -30.2% | 83,058 | -16.6% | 0.00% | – |
Q2 2021 | $434,000 | -6.1% | 99,565 | -2.1% | 0.00% | – |
Q1 2021 | $462,000 | +62.7% | 101,676 | +105.7% | 0.00% | – |
Q4 2020 | $284,000 | +40.6% | 49,434 | +76.8% | 0.00% | – |
Q3 2020 | $202,000 | +818.2% | 27,957 | +152.8% | 0.00% | – |
Q4 2019 | $22,000 | -91.2% | 11,059 | -77.2% | 0.00% | – |
Q3 2019 | $249,000 | -36.0% | 48,590 | -10.5% | 0.00% | -100.0% |
Q2 2019 | $389,000 | -43.1% | 54,293 | +5.4% | 0.00% | 0.0% |
Q1 2019 | $684,000 | +5.7% | 51,513 | -37.3% | 0.00% | 0.0% |
Q4 2018 | $647,000 | -23.4% | 82,205 | +7.7% | 0.00% | 0.0% |
Q3 2018 | $845,000 | +48.5% | 76,306 | +80.0% | 0.00% | 0.0% |
Q2 2018 | $569,000 | +3.6% | 42,399 | +0.4% | 0.00% | 0.0% |
Q1 2018 | $549,000 | +12.3% | 42,230 | -20.5% | 0.00% | 0.0% |
Q4 2017 | $489,000 | +71.6% | 53,148 | +50.6% | 0.00% | 0.0% |
Q3 2017 | $285,000 | – | 35,300 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Saturn V Capital Management LP | 1,629,464 | $14,208,926 | 10.61% |
Lynx1 Capital Management LP | 1,369,927 | $11,945,763 | 9.96% |
Versant Venture Management, LLC | 543,753 | $4,741,526 | 9.88% |
Foresite Capital Management IV, LLC | 1,787,094 | $15,583,460 | 8.09% |
Octagon Capital Advisors LP | 4,570,918 | $39,858,405 | 5.74% |
ACUTA CAPITAL PARTNERS, LLC | 878,500 | $7,660,520 | 5.64% |
TCG Crossover Management, LLC | 3,048,257 | $26,580,801 | 5.18% |
Affinity Asset Advisors, LLC | 1,083,118 | $9,444,789 | 3.12% |
Altium Capital Management LP | 620,000 | $5,406,400 | 3.00% |
Bain Capital Life Sciences Investors, LLC | 2,500,000 | $21,800 | 2.72% |